{"success":true,"data":{"pressRelease":{"id":"111016","rtpr_id":"nGNX6mjMFR","ticker":"SION","exchange":"NASDAQ","all_tickers":["SION"],"title":"Sionna Therapeutics Reports Second Quarter 2026 Financial Results","author":"Globe Newswire","published_at":"2026-08-06T11:00:04.789Z","article_body":"PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer\nSION-719 as an add-on to standard of care is on track for topline data summer\nof 2026\n\nPhase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual\ncombinations with SION-2222 and with SION-109 also is on track for topline\ndata summer of 2026\n\nMaintained strong cash position with $268.3 million in cash and cash\nequivalents, expected to fund operations into 2028\n\nWALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc.\n(Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to\nrevolutionize the current treatment paradigm for cystic fibrosis (CF) today\nreported financial results for the second quarter ended June 30, 2026, and\nprovided a business update.\n\n“We continued to advance our clinical NBD1 stabilizer programs during the\nsecond quarter as we approach two important clinical milestones this\nsummer,” said Mike Cloonan, President and Chief Executive Officer of Sionna.\n“We remain focused on execution and delivering topline data from both our\nPhase 2a proof-of-concept trial and our Phase 1 dual combination trial.\nTogether, these studies have the potential to further validate our core belief\nthat directly stabilizing NBD1 is central to restoring CFTR function and\ntransforming the treatment paradigm for people living with cystic fibrosis.\"\n\nPipeline Updates\n* PreciSION CF Phase 2a Proof-of-Concept Trial with SION-719 Is On Track:\nThe PreciSION CF Phase 2a proof-of-concept (POC) trial (NCT07108153\n(https://clinicaltrials.gov/study/NCT07108153)) is evaluating SION-719 as an\nadd-on to standard of care (SOC) in CF participants. The trial is evaluating\nthe safety, tolerability, and pharmacokinetics (PK) of SION-719 when\nadministered with SOC and assessing change in CFTR function as measured by\nsweat chloride levels. In April 2026, Sionna announced\n(https://investors.sionnatx.com/news-releases/news-release-details/sionna-therapeutics-completes-enrollment-precision-cf-phase-2a)\nit had completed enrollment. Topline data from this trial are on track for\nthis summer.\n* Phase 1 Dual Combination Trial with SION-451 and Complementary Modulators Is\nOn Track: The Phase 1 trial (NCT07035990\n(https://clinicaltrials.gov/study/NCT07035990?cond=Cystic%20Fibrosis&intr=SION-451&rank=1)) is\nevaluating SION-451 in proprietary dual combinations with SION-2222\n(galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and\nwith SION-109, an intracellular loop 4 (ICL4)-directed CFTR corrector, in\nhealthy volunteers. Topline data from this trial are on track for this\nsummer.\n* Presented Encore Data at 49(th) European Cystic Fibrosis Conference: In June\n2026, Sionna presented encore clinical and nonclinical data at the 49(th)\nEuropean Cystic Fibrosis Conference (ECFS) in Lisbon, Portugal. Presentations\nhighlighted previously reported Phase 1 data for the Company's clinical-stage\nNBD1 stabilizers, SION-719 and SION-451, and nonclinical data demonstrating\nthe potential of NBD1 stabilizers to increase F508del-CFTR protein half-life\nup to wild-type levels when used alone or in combination with complementary\nCFTR modulators. The same data will also be presented at the 16th Australasian\nCystic Fibrosis Conference taking place August 7(th)-9(th) in Geelong,\nAustralia.\nFinancial Results for the Quarter Ended June 30, 2026\n\nResearch and Development Expenses: Research and development expenses\nwere $21.9 million for the second quarter of 2026, compared to $15.4 million\nfor the second quarter of 2025. These increases were mainly driven by\ndevelopment expenses to support the advancement of Sionna’s clinical\npipeline and personnel-related costs, including stock-based compensation\nexpenses, to support the Company’s continued growth and operational\nactivities.\n\nGeneral and Administrative Expenses: General and administrative expenses\nwere $10.6 million for the second quarter of 2026, compared to $6.5 million\nfor the second quarter of 2025. These increases were primarily due to\npersonnel-related costs, including stock-based compensation expenses, to\nsupport the Company’s continued growth and operational activities.\n\nNet Loss: Net loss was $29.9 million for the second quarter of 2026, compared\nto a net loss of $18.1 million for the second quarter of 2025. \n\nCash and Cash Equivalents: Cash, cash equivalents and marketable securities\ntotaled $268.3 million as of June 30, 2026. Sionna expects its current cash\nposition to fund operations into 2028. \n\nAbout Sionna Therapeutics \nSionna Therapeutics is a clinical-stage biopharmaceutical company on a mission\nto revolutionize the current treatment paradigm for cystic fibrosis (CF) by\ndeveloping novel medicines that normalize the function of the cystic fibrosis\ntransmembrane conductance regulator (CFTR) protein. Sionna’s goal is to\ndeliver differentiated medicines for people living with CF that can restore\ntheir CFTR function to as close to normal as possible by directly stabilizing\nCFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central\nto potentially unlocking dramatic improvements in clinical outcomes and\nquality of life for people with CF. Leveraging more than a decade of the\nco-founders’ research on NBD1, Sionna is advancing a pipeline of small\nmolecules engineered to correct the defects caused by the F508del genetic\nmutation, which occurs in NBD1. Sionna is also developing a portfolio of\ncomplementary CFTR modulators that are designed to work synergistically with\nits NBD1 stabilizers to improve CFTR function. For more information about\nSionna, visit www.sionnatx.com.\n\nSionna intends to use its Investor Relations website as a means of disclosing\nmaterial nonpublic information and for complying with its disclosure\nobligations under Regulation FD. Accordingly, investors should monitor\nSionna’s Investor Relations website, in addition to following Sionna’s\npress releases, SEC filings, public conference calls, presentations, and\nwebcasts.\n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including,\nwithout limitation, implied and express statements about Sionna’s beliefs\nand expectations regarding: its goal of transforming the treatment paradigm\nfor CF and providing clinically meaningful benefit for CF participants; the\npotential of Sionna’s product candidates to expand therapeutic options for\npeople with CF; the initiation, timing, progress and results of Sionna’s\nresearch and development programs, clinical trials and studies, including the\ntiming of topline data from Sionna’s Phase 2a proof-of-concept trial and\nPhase 1 dual combination trial; the ability of clinical trials to demonstrate\nsafety and efficacy of Sionna’s product candidates; the ability of\nSionna’s nonclinical studies or earlier clinical trials to predict later\nclinical trial results; and financial projections and expectations regarding\nthe time period in which Sionna’s capital resources will be sufficient to\nfund its anticipated operations, including cash runway, use of capital,\nexpenses and other financial results. In some cases, the forward-looking\nstatements can be identified by terms such as “may,” “will,”\n“should,” “would,” “expect,” “plan,” “anticipate,”\n“could,” “intend,” “target,” “project,” “believe,”\n“estimate,” “predict,” “potential” or “continue” or the\nnegative of these terms or other similar expressions. Any forward-looking\nstatements in this press release are based on management’s current\nexpectations and beliefs and are subject to a number of risks, uncertainties\nand important factors that may cause actual events or results to differ\nmaterially from those expressed or implied by the forward-looking statements\ncontained in this press release. Factors that could cause actual results to\ndiffer include, but are not limited to, risks and uncertainties inherent in\nthe development of product candidates, including uncertainties concerning the\ninitiation, timing, progress, and results of Sionna’s ongoing, planned and\nfuture clinical trials and studies; the Company’s ability to replicate\npositive results from earlier nonclinical studies or clinical trials in\ncurrent or future clinical trials; Sionna’s ability to demonstrate that its\nNBD1 stabilizers, complementary CFTR modulators, and any potential future\nproduct candidates are safe and effective for their proposed indications;\nregulatory developments in the United States and foreign countries; the\ncompetitive landscape for CF treatments, including existing therapies; and\ngeneral economic, industry and market conditions. These risks and\nuncertainties are described in the section entitled “Risk Factors” in\nSionna’s most recent Annual Report on Form 10-K as well as any subsequent\nfilings with the Securities and Exchange Commission. The events and\ncircumstances reflected in the forward-looking statements may not be achieved\nor occur. In addition, any forward-looking statements represent Sionna’s\nviews only as of today and should not be relied upon as representing its views\nas of any subsequent date. Sionna explicitly disclaims any obligation to\nupdate any forward-looking statements except as required by law. No\nrepresentations or warranties (expressed or implied) are made about the\naccuracy of any such forward-looking statements.\n\nInvestor Contact \nJuliet Labadorf \nir@sionnatx.com \n\nMedia Contact \nSarah Spencer\nmedia@sionnatx.com\n\n                                                                                                                                                                      \n Sionna Therapeutics, Inc.                                                                                                                                            \n Consolidated Statements of Operations                                                                                                                                \n (In thousands, except per share data)                                                                                                                                \n (Unaudited)                                                                                                                                                          \n                                                                                                                                                                      \n                                                                Three Months Ended                                   Six Months Ended                                 \n                                                                                                            June 30,                                             June   \n                                                                                                                                                                 30,    \n                                                                2026                       2025                      2026                       2025                  \n Operating expenses:                                                                                                                                                  \n Research and development                                       $    21,864                $    15,383               $    40,827                $    29,051           \n General and administrative                                          10,606                     6,523                     21,242                     12,514           \n Total operating expenses                                            32,470                     21,906                    62,069                     41,565           \n Loss from operations                                                (32,470     )              (21,906     )             (62,069     )              (41,565     )    \n Other income:                                                                                                                                                        \n Interest income                                                     2,587                      3,667                     5,407                      6,667            \n Other income (expense), net                                         (3          )              171                       (3          )              348              \n Total other income                                                  2,584                      3,838                     5,404                      7,015            \n Net loss                                                       $    (29,886     )         $    (18,068     )        $    (56,665     )         $    (34,550     )    \n Net loss per share, basic and diluted                          $    (0.66       )         $    (0.41       )        $    (1.25       )         $    (0.98       )    \n Weighted-average common shares outstanding, basic and diluted       45,148,971                 44,116,997                45,306,105                 35,404,928       \n                                                                                                                                                                      \n\n\n\n Sionna Therapeutics, Inc.                                                                                                                         \n Selected Consolidated Balance Sheet Data                                                                                                          \n (In thousands)                                                                                                                                    \n (Unaudited)                                                                                                                                       \n                                                                                                                                                   \n                                                    June 30,                                                                December 31,           \n                                                    2026                                                                    2025                   \n Cash, cash equivalents, and marketable securities  $                 268,253                                               $      310,302         \n Working capital (1)                                                  205,348                                                      229,707         \n Total assets                                                         283,249                                                      325,953         \n Total stockholders’ equity                                           265,775                                                      306,833         \n                                                                                                                                                   \n (1)Sionna defines working capital as current assets minus current liabilities.                                                                    \n                                                                                                                                                   \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0cda8c25-e758-4f0d-86f2-875df8411a9a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6mjMFR","title":"Sionna Therapeutics Reports Second Quarter 2026 Financial Results","author":"Globe Newswire","ticker":"SION","created":"2026-08-06T11:00:04.789Z","tickers":["SION"],"exchange":"NASDAQ","article_body":"PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer\nSION-719 as an add-on to standard of care is on track for topline data summer\nof 2026\n\nPhase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual\ncombinations with SION-2222 and with SION-109 also is on track for topline\ndata summer of 2026\n\nMaintained strong cash position with $268.3 million in cash and cash\nequivalents, expected to fund operations into 2028\n\nWALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc.\n(Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to\nrevolutionize the current treatment paradigm for cystic fibrosis (CF) today\nreported financial results for the second quarter ended June 30, 2026, and\nprovided a business update.\n\n“We continued to advance our clinical NBD1 stabilizer programs during the\nsecond quarter as we approach two important clinical milestones this\nsummer,” said Mike Cloonan, President and Chief Executive Officer of Sionna.\n“We remain focused on execution and delivering topline data from both our\nPhase 2a proof-of-concept trial and our Phase 1 dual combination trial.\nTogether, these studies have the potential to further validate our core belief\nthat directly stabilizing NBD1 is central to restoring CFTR function and\ntransforming the treatment paradigm for people living with cystic fibrosis.\"\n\nPipeline Updates\n* PreciSION CF Phase 2a Proof-of-Concept Trial with SION-719 Is On Track:\nThe PreciSION CF Phase 2a proof-of-concept (POC) trial (NCT07108153\n(https://clinicaltrials.gov/study/NCT07108153)) is evaluating SION-719 as an\nadd-on to standard of care (SOC) in CF participants. The trial is evaluating\nthe safety, tolerability, and pharmacokinetics (PK) of SION-719 when\nadministered with SOC and assessing change in CFTR function as measured by\nsweat chloride levels. In April 2026, Sionna announced\n(https://investors.sionnatx.com/news-releases/news-release-details/sionna-therapeutics-completes-enrollment-precision-cf-phase-2a)\nit had completed enrollment. Topline data from this trial are on track for\nthis summer.\n* Phase 1 Dual Combination Trial with SION-451 and Complementary Modulators Is\nOn Track: The Phase 1 trial (NCT07035990\n(https://clinicaltrials.gov/study/NCT07035990?cond=Cystic%20Fibrosis&intr=SION-451&rank=1)) is\nevaluating SION-451 in proprietary dual combinations with SION-2222\n(galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and\nwith SION-109, an intracellular loop 4 (ICL4)-directed CFTR corrector, in\nhealthy volunteers. Topline data from this trial are on track for this\nsummer.\n* Presented Encore Data at 49(th) European Cystic Fibrosis Conference: In June\n2026, Sionna presented encore clinical and nonclinical data at the 49(th)\nEuropean Cystic Fibrosis Conference (ECFS) in Lisbon, Portugal. Presentations\nhighlighted previously reported Phase 1 data for the Company's clinical-stage\nNBD1 stabilizers, SION-719 and SION-451, and nonclinical data demonstrating\nthe potential of NBD1 stabilizers to increase F508del-CFTR protein half-life\nup to wild-type levels when used alone or in combination with complementary\nCFTR modulators. The same data will also be presented at the 16th Australasian\nCystic Fibrosis Conference taking place August 7(th)-9(th) in Geelong,\nAustralia.\nFinancial Results for the Quarter Ended June 30, 2026\n\nResearch and Development Expenses: Research and development expenses\nwere $21.9 million for the second quarter of 2026, compared to $15.4 million\nfor the second quarter of 2025. These increases were mainly driven by\ndevelopment expenses to support the advancement of Sionna’s clinical\npipeline and personnel-related costs, including stock-based compensation\nexpenses, to support the Company’s continued growth and operational\nactivities.\n\nGeneral and Administrative Expenses: General and administrative expenses\nwere $10.6 million for the second quarter of 2026, compared to $6.5 million\nfor the second quarter of 2025. These increases were primarily due to\npersonnel-related costs, including stock-based compensation expenses, to\nsupport the Company’s continued growth and operational activities.\n\nNet Loss: Net loss was $29.9 million for the second quarter of 2026, compared\nto a net loss of $18.1 million for the second quarter of 2025. \n\nCash and Cash Equivalents: Cash, cash equivalents and marketable securities\ntotaled $268.3 million as of June 30, 2026. Sionna expects its current cash\nposition to fund operations into 2028. \n\nAbout Sionna Therapeutics \nSionna Therapeutics is a clinical-stage biopharmaceutical company on a mission\nto revolutionize the current treatment paradigm for cystic fibrosis (CF) by\ndeveloping novel medicines that normalize the function of the cystic fibrosis\ntransmembrane conductance regulator (CFTR) protein. Sionna’s goal is to\ndeliver differentiated medicines for people living with CF that can restore\ntheir CFTR function to as close to normal as possible by directly stabilizing\nCFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central\nto potentially unlocking dramatic improvements in clinical outcomes and\nquality of life for people with CF. Leveraging more than a decade of the\nco-founders’ research on NBD1, Sionna is advancing a pipeline of small\nmolecules engineered to correct the defects caused by the F508del genetic\nmutation, which occurs in NBD1. Sionna is also developing a portfolio of\ncomplementary CFTR modulators that are designed to work synergistically with\nits NBD1 stabilizers to improve CFTR function. For more information about\nSionna, visit www.sionnatx.com.\n\nSionna intends to use its Investor Relations website as a means of disclosing\nmaterial nonpublic information and for complying with its disclosure\nobligations under Regulation FD. Accordingly, investors should monitor\nSionna’s Investor Relations website, in addition to following Sionna’s\npress releases, SEC filings, public conference calls, presentations, and\nwebcasts.\n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including,\nwithout limitation, implied and express statements about Sionna’s beliefs\nand expectations regarding: its goal of transforming the treatment paradigm\nfor CF and providing clinically meaningful benefit for CF participants; the\npotential of Sionna’s product candidates to expand therapeutic options for\npeople with CF; the initiation, timing, progress and results of Sionna’s\nresearch and development programs, clinical trials and studies, including the\ntiming of topline data from Sionna’s Phase 2a proof-of-concept trial and\nPhase 1 dual combination trial; the ability of clinical trials to demonstrate\nsafety and efficacy of Sionna’s product candidates; the ability of\nSionna’s nonclinical studies or earlier clinical trials to predict later\nclinical trial results; and financial projections and expectations regarding\nthe time period in which Sionna’s capital resources will be sufficient to\nfund its anticipated operations, including cash runway, use of capital,\nexpenses and other financial results. In some cases, the forward-looking\nstatements can be identified by terms such as “may,” “will,”\n“should,” “would,” “expect,” “plan,” “anticipate,”\n“could,” “intend,” “target,” “project,” “believe,”\n“estimate,” “predict,” “potential” or “continue” or the\nnegative of these terms or other similar expressions. Any forward-looking\nstatements in this press release are based on management’s current\nexpectations and beliefs and are subject to a number of risks, uncertainties\nand important factors that may cause actual events or results to differ\nmaterially from those expressed or implied by the forward-looking statements\ncontained in this press release. Factors that could cause actual results to\ndiffer include, but are not limited to, risks and uncertainties inherent in\nthe development of product candidates, including uncertainties concerning the\ninitiation, timing, progress, and results of Sionna’s ongoing, planned and\nfuture clinical trials and studies; the Company’s ability to replicate\npositive results from earlier nonclinical studies or clinical trials in\ncurrent or future clinical trials; Sionna’s ability to demonstrate that its\nNBD1 stabilizers, complementary CFTR modulators, and any potential future\nproduct candidates are safe and effective for their proposed indications;\nregulatory developments in the United States and foreign countries; the\ncompetitive landscape for CF treatments, including existing therapies; and\ngeneral economic, industry and market conditions. These risks and\nuncertainties are described in the section entitled “Risk Factors” in\nSionna’s most recent Annual Report on Form 10-K as well as any subsequent\nfilings with the Securities and Exchange Commission. The events and\ncircumstances reflected in the forward-looking statements may not be achieved\nor occur. In addition, any forward-looking statements represent Sionna’s\nviews only as of today and should not be relied upon as representing its views\nas of any subsequent date. Sionna explicitly disclaims any obligation to\nupdate any forward-looking statements except as required by law. No\nrepresentations or warranties (expressed or implied) are made about the\naccuracy of any such forward-looking statements.\n\nInvestor Contact \nJuliet Labadorf \nir@sionnatx.com \n\nMedia Contact \nSarah Spencer\nmedia@sionnatx.com\n\n                                                                                                                                                                      \n Sionna Therapeutics, Inc.                                                                                                                                            \n Consolidated Statements of Operations                                                                                                                                \n (In thousands, except per share data)                                                                                                                                \n (Unaudited)                                                                                                                                                          \n                                                                                                                                                                      \n                                                                Three Months Ended                                   Six Months Ended                                 \n                                                                                                            June 30,                                             June   \n                                                                                                                                                                 30,    \n                                                                2026                       2025                      2026                       2025                  \n Operating expenses:                                                                                                                                                  \n Research and development                                       $    21,864                $    15,383               $    40,827                $    29,051           \n General and administrative                                          10,606                     6,523                     21,242                     12,514           \n Total operating expenses                                            32,470                     21,906                    62,069                     41,565           \n Loss from operations                                                (32,470     )              (21,906     )             (62,069     )              (41,565     )    \n Other income:                                                                                                                                                        \n Interest income                                                     2,587                      3,667                     5,407                      6,667            \n Other income (expense), net                                         (3          )              171                       (3          )              348              \n Total other income                                                  2,584                      3,838                     5,404                      7,015            \n Net loss                                                       $    (29,886     )         $    (18,068     )        $    (56,665     )         $    (34,550     )    \n Net loss per share, basic and diluted                          $    (0.66       )         $    (0.41       )        $    (1.25       )         $    (0.98       )    \n Weighted-average common shares outstanding, basic and diluted       45,148,971                 44,116,997                45,306,105                 35,404,928       \n                                                                                                                                                                      \n\n\n\n Sionna Therapeutics, Inc.                                                                                                                         \n Selected Consolidated Balance Sheet Data                                                                                                          \n (In thousands)                                                                                                                                    \n (Unaudited)                                                                                                                                       \n                                                                                                                                                   \n                                                    June 30,                                                                December 31,           \n                                                    2026                                                                    2025                   \n Cash, cash equivalents, and marketable securities  $                 268,253                                               $      310,302         \n Working capital (1)                                                  205,348                                                      229,707         \n Total assets                                                         283,249                                                      325,953         \n Total stockholders’ equity                                           265,775                                                      306,833         \n                                                                                                                                                   \n (1)Sionna defines working capital as current assets minus current liabilities.                                                                    \n                                                                                                                                                   \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0cda8c25-e758-4f0d-86f2-875df8411a9a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-06T11:00:07.224478384Z","server_sent_at_ms":1786014007224},"received_at":"2026-08-06T11:00:13.193Z","source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340068/0/en/sionna-therapeutics-reports-second-quarter-2026-financial-results.html"},"analysis":{"id":"100022","press_release_id":"111016","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Net loss widened to $29.9M from $18.1M YoY","R&D expenses increased 42% YoY to $21.9M","G&A expenses increased 63% YoY to $10.6M"],"eventType":"earnings","narrative":"Sionna reported a Q2 net loss of $29.9 million, or $0.66 per share, widening from a loss of $18.1 million in the prior year due to higher R&D and administrative costs.\n\nThe company ended the quarter with $268.3 million in cash and equivalents, which management expects to fund operations into 2028.\n\nKey clinical programs remain on schedule, with topline data from the Phase 2a PreciSION CF trial of SION-719 and the Phase 1 dual combination trial of SION-451 expected this summer.","sentiment":"mixed","agentHooks":{"shouldPost":false,"suggestedAngle":"Burn increases as SION heads into imminent Phase 2a/Phase 1 data readouts this summer."},"keyFigures":{"guidance":"PreciSION CF Phase 2a (SION-719) and Phase 1 (SION-451) topline data on track for summer 2026","customDimensions":{"net_loss":29900000,"ga_expenses":10600000,"rd_expenses":21900000,"cash_position":268300000}},"quotedText":"We continued to advance our clinical NBD1 stabilizer programs during the second quarter as we approach two important clinical milestones this summer","namedEntities":{"people":[{"name":"Mike Cloonan","role":"President and Chief Executive Officer"}],"products":["SION-719","SION-451","SION-2222","SION-109","galicaftor"],"companies":[{"name":"Sionna Therapeutics, Inc.","ticker":"SION"}],"dollarAmounts":[{"amount":"$21.9 million","context":"Q2 2026 Research and development expenses"},{"amount":"$15.4 million","context":"Q2 2025 Research and development expenses"},{"amount":"$10.6 million","context":"Q2 2026 General and administrative expenses"},{"amount":"$6.5 million","context":"Q2 2025 General and administrative expenses"},{"amount":"$29.9 million","context":"Q2 2026 Net loss"},{"amount":"$18.1 million","context":"Q2 2025 Net loss"},{"amount":"$268.3 million","context":"Cash, cash equivalents and marketable securities as of June 30, 2026"}]},"materialImpact":{"score":3,"reasoning":"Routine earnings release for a clinical-stage biotech showing increased operating losses but confirming timelines for imminent binary data readouts this summer."},"tickerRelevance":{"others":[],"primary":"SION"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-earnings","sectorWeight":"biotech"}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"mixed","material_impact_score":3,"narrative":"Sionna reported a Q2 net loss of $29.9 million, or $0.66 per share, widening from a loss of $18.1 million in the prior year due to higher R&D and administrative costs.\n\nThe company ended the quarter with $268.3 million in cash and equivalents, which management expects to fund operations into 2028.\n\nKey clinical programs remain on schedule, with topline data from the Phase 2a PreciSION CF trial of SION-719 and the Phase 1 dual combination trial of SION-451 expected this summer.","key_figures":{"guidance":"PreciSION CF Phase 2a (SION-719) and Phase 1 (SION-451) topline data on track for summer 2026","customDimensions":{"net_loss":29900000,"ga_expenses":10600000,"rd_expenses":21900000,"cash_position":268300000}},"named_entities":{"people":[{"name":"Mike Cloonan","role":"President and Chief Executive Officer"}],"products":["SION-719","SION-451","SION-2222","SION-109","galicaftor"],"companies":[{"name":"Sionna Therapeutics, Inc.","ticker":"SION"}],"dollarAmounts":[{"amount":"$21.9 million","context":"Q2 2026 Research and development expenses"},{"amount":"$15.4 million","context":"Q2 2025 Research and development expenses"},{"amount":"$10.6 million","context":"Q2 2026 General and administrative expenses"},{"amount":"$6.5 million","context":"Q2 2025 General and administrative expenses"},{"amount":"$29.9 million","context":"Q2 2026 Net loss"},{"amount":"$18.1 million","context":"Q2 2025 Net loss"},{"amount":"$268.3 million","context":"Cash, cash equivalents and marketable securities as of June 30, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T15:48:29.096Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-earnings","sectorWeight":"biotech"}},"durationMs":363499,"modelName":"glm-4.7"}}